On this page
Triple Antibiotic Plus
Polymyxin B Sulfate, Bacitracin Zinc, Neomycin Sulfate, Pramoxine HCl · Ointment
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Bacitracin Zinc | 500 [USP'U]/g | 204602 | View |
| Neomycin | 3.5 mg/g | 1359350 | View |
| Neomycin Sulfate | 3.5 mg/g | 204602 | View |
| Polymyxin B Sulfate | 10000 [USP'U]/g | 204602 | View |
| Pramoxine Hydrochloride | 10 mg/g | 1234532 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Aminoglycoside Antibacterial [EPC] | EPC | All 66 members |
| Aminoglycosides [CS] | CS | All 66 members |
| Decreased Cell Wall Synthesis & Repair [PE] | PE | All 41 members |
| Polymyxin-class Antibacterial [EPC] | EPC | All 55 members |
| Polymyxins [CS] | CS | All 55 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 000004-004 | PAREDRINE | SOLUTION/DROPS | HYDROXYAMPHETAMINE HYDROBROMIDE | Discontinued | — |
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 11 | Labeling | Approved | May 26, 1987 | — |
| Supplement | 10 | Labeling | Approved | May 8, 1980 | — |
| Original application | 1 | Approved | July 16, 1969 | Unknown |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20241006). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingUSES first aid to help prevent infection and provide temporary relief of pain or discomfort in minor • cuts • scrapes • burns
Purpose
openFDA Drug LabelingActive ingredients (in each gram) Purpose Bacitracin zinc 500 units First aid antibiotic Neomycin 3.5 mg First aid antibiotic Polymyxin B sulfate 10,000 units First aid antibiotic Pramoxine hydrochloride 10.0 mg Topical analgesic
Dosage and Administration
openFDA Drug LabelingDIRECTIONS • adults and children 2 years of age and older • clean the affected area • apply a small amount of this product (an amount equal to the surface area of the tip of a finger) on the area 1 to 3 times daily • may be covered with a sterile bandage • children under 2 years of age: consult a doctor
Warnings
openFDA Drug LabelingWarnings For external use only. Do not use • if you are allergic to any of the ingredients • in the eyes • over large areas of the body Ask a doctor before use if you have • deep or puncture wounds • animal bites • serious burns Stop use and ask a doctor if • you need to use longer than 1 week • condition persists or gets worse • symptoms persist for more than 1 week, or clear up and occur again within a few days • rash or other allergic reaction develops Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
Do Not Use
openFDA Drug LabelingDo not use • if you are allergic to any of the ingredients • in the eyes • over large areas of the body
Ask a Doctor
openFDA Drug LabelingAsk a doctor before use if you have • deep or puncture wounds • animal bites • serious burns
Stop Use
openFDA Drug LabelingStop use and ask a doctor if • you need to use longer than 1 week • condition persists or gets worse • symptoms persist for more than 1 week, or clear up and occur again within a few days • rash or other allergic reaction develops
Active Ingredient
openFDA Drug LabelingActive ingredients (in each gram) Purpose Bacitracin zinc 500 units First aid antibiotic Neomycin 3.5 mg First aid antibiotic Polymyxin B sulfate 10,000 units First aid antibiotic Pramoxine hydrochloride 10.0 mg Topical analgesic
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: NEOMYCIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0713-0622-31 | 0713-0622 | Cosette Pharmaceuticals, Inc. | 28.4 g in 1 TUBE (0713-0622-31) | February 28, 1998 |
| 37808-679-64 | 37808-679 | H E B | 1 TUBE in 1 CARTON (37808-679-64) / 28 g in 1 TUBE | November 5, 2010 |
| 0713-0622 | 0713-0622 | Cosette Pharmaceuticals, Inc. | — | February 28, 1998 |
| 37808-679 | 37808-679 | H E B | — | November 5, 2010 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 10 sections on this page.